KARYOPHARM THERAPEUTICS INC (KPTI) Fundamental Analysis & Valuation

NASDAQ:KPTI • US48576U2050

Current stock price

8 USD
-0.16 (-1.96%)
At close:
8 USD
0 (0%)
After Hours:

This KPTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. KPTI Profitability Analysis

1.1 Basic Checks

  • In the past year KPTI has reported negative net income.
  • In the past year KPTI has reported a negative cash flow from operations.
  • KPTI had negative earnings in each of the past 5 years.
  • KPTI had a negative operating cash flow in each of the past 5 years.
KPTI Yearly Net Income VS EBIT VS OCF VS FCFKPTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -180.82%, KPTI is doing worse than 86.65% of the companies in the same industry.
Industry RankSector Rank
ROA -180.82%
ROE N/A
ROIC N/A
ROA(3y)-95.61%
ROA(5y)-74.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KPTI Yearly ROA, ROE, ROICKPTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500

1.3 Margins

  • KPTI's Gross Margin of 95.93% is amongst the best of the industry. KPTI outperforms 96.13% of its industry peers.
  • KPTI's Gross Margin has been stable in the last couple of years.
  • KPTI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.26%
GM growth 5Y-0.33%
KPTI Yearly Profit, Operating, Gross MarginsKPTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. KPTI Health Analysis

2.1 Basic Checks

  • KPTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, KPTI has more shares outstanding
  • KPTI has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, KPTI has a worse debt to assets ratio.
KPTI Yearly Shares OutstandingKPTI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
KPTI Yearly Total Debt VS Total AssetsKPTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -23.74, we must say that KPTI is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -23.74, KPTI is doing worse than 85.69% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -23.74
ROIC/WACCN/A
WACC7.44%
KPTI Yearly LT Debt VS Equity VS FCFKPTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M 300M

2.3 Liquidity

  • A Current Ratio of 1.12 indicates that KPTI should not have too much problems paying its short term obligations.
  • KPTI has a Current ratio of 1.12. This is amonst the worse of the industry: KPTI underperforms 85.88% of its industry peers.
  • KPTI has a Quick Ratio of 1.08. This is a normal value and indicates that KPTI is financially healthy and should not expect problems in meeting its short term obligations.
  • KPTI has a worse Quick ratio (1.08) than 85.49% of its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 1.08
KPTI Yearly Current Assets VS Current LiabilitesKPTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. KPTI Growth Analysis

3.1 Past

  • KPTI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.65%.
  • KPTI shows a small growth in Revenue. In the last year, the Revenue has grown by 0.57%.
  • The Revenue has been growing slightly by 6.21% on average over the past years.
EPS 1Y (TTM)-30.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.33%
Revenue 1Y (TTM)0.57%
Revenue growth 3Y-2.4%
Revenue growth 5Y6.21%
Sales Q2Q%11.58%

3.2 Future

  • KPTI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.45% yearly.
  • Based on estimates for the next years, KPTI will show a very strong growth in Revenue. The Revenue will grow by 36.01% on average per year.
EPS Next Y65.42%
EPS Next 2Y31.19%
EPS Next 3Y23.99%
EPS Next 5Y17.45%
Revenue Next Year-6.53%
Revenue Next 2Y6.94%
Revenue Next 3Y13.43%
Revenue Next 5Y36.01%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KPTI Yearly Revenue VS EstimatesKPTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
KPTI Yearly EPS VS EstimatesKPTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

1

4. KPTI Valuation Analysis

4.1 Price/Earnings Ratio

  • KPTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year KPTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KPTI Price Earnings VS Forward Price EarningsKPTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KPTI Per share dataKPTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as KPTI's earnings are expected to grow with 23.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.19%
EPS Next 3Y23.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KPTI Dividend Analysis

5.1 Amount

  • No dividends for KPTI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KPTI Fundamentals: All Metrics, Ratios and Statistics

KARYOPHARM THERAPEUTICS INC

NASDAQ:KPTI (4/10/2026, 8:00:02 PM)

After market: 8 0 (0%)

8

-0.16 (-1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)04-30
Inst Owners60.48%
Inst Owner Change0%
Ins Owners1.99%
Ins Owner Change2.74%
Market Cap180.32M
Revenue(TTM)146.07M
Net Income(TTM)-196.04M
Analysts83.08
Price Target12.24 (53%)
Short Float %20.99%
Short Ratio3.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.38%
Min EPS beat(2)-19.63%
Max EPS beat(2)-9.14%
EPS beat(4)1
Avg EPS beat(4)0.74%
Min EPS beat(4)-19.63%
Max EPS beat(4)35.04%
EPS beat(8)5
Avg EPS beat(8)21.41%
EPS beat(12)7
Avg EPS beat(12)15.77%
EPS beat(16)10
Avg EPS beat(16)13.35%
Revenue beat(2)1
Avg Revenue beat(2)-0.03%
Min Revenue beat(2)-4.84%
Max Revenue beat(2)4.78%
Revenue beat(4)2
Avg Revenue beat(4)-3.97%
Min Revenue beat(4)-16.5%
Max Revenue beat(4)4.78%
Revenue beat(8)4
Avg Revenue beat(8)-2.4%
Revenue beat(12)6
Avg Revenue beat(12)-2.1%
Revenue beat(16)9
Avg Revenue beat(16)1.08%
PT rev (1m)-22.08%
PT rev (3m)-17.81%
EPS NQ rev (1m)-9.53%
EPS NQ rev (3m)26.86%
EPS NY rev (1m)11.97%
EPS NY rev (3m)33.06%
Revenue NQ rev (1m)-1.15%
Revenue NQ rev (3m)-9.25%
Revenue NY rev (1m)-1.01%
Revenue NY rev (3m)-5.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.23
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.13
EYN/A
EPS(NY)-4.54
Fwd EYN/A
FCF(TTM)-3.34
FCFYN/A
OCF(TTM)-3.34
OCFYN/A
SpS6.48
BVpS-13
TBVpS-13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -180.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.93%
FCFM N/A
ROA(3y)-95.61%
ROA(5y)-74.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.26%
GM growth 5Y-0.33%
F-Score3
Asset Turnover1.35
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 1.08
Altman-Z -23.74
F-Score3
WACC7.44%
ROIC/WACCN/A
Cap/Depr(3y)13.92%
Cap/Depr(5y)17.54%
Cap/Sales(3y)0.03%
Cap/Sales(5y)0.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.33%
EPS Next Y65.42%
EPS Next 2Y31.19%
EPS Next 3Y23.99%
EPS Next 5Y17.45%
Revenue 1Y (TTM)0.57%
Revenue growth 3Y-2.4%
Revenue growth 5Y6.21%
Sales Q2Q%11.58%
Revenue Next Year-6.53%
Revenue Next 2Y6.94%
Revenue Next 3Y13.43%
Revenue Next 5Y36.01%
EBIT growth 1Y24.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.88%
OCF growth 3YN/A
OCF growth 5YN/A

KARYOPHARM THERAPEUTICS INC / KPTI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for KARYOPHARM THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to KPTI.


What is the valuation status for KPTI stock?

ChartMill assigns a valuation rating of 1 / 10 to KARYOPHARM THERAPEUTICS INC (KPTI). This can be considered as Overvalued.


Can you provide the profitability details for KARYOPHARM THERAPEUTICS INC?

KARYOPHARM THERAPEUTICS INC (KPTI) has a profitability rating of 1 / 10.


What is the earnings growth outlook for KARYOPHARM THERAPEUTICS INC?

The Earnings per Share (EPS) of KARYOPHARM THERAPEUTICS INC (KPTI) is expected to grow by 65.42% in the next year.